3rd Line and beyond

3rd Line and beyond

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

Dr. Karen Reckamp, MD, MS, City of Hope Comprehensive Cancer Center in Duarte, California joined GRACE to discuss the role of immunotherapy for previously treated patients with non-small cell lung cancer.
Cancer Journey:
Cancer Type:
,
,
Download the speaker presentations and handouts from the Targeted Therapies Patient Forum in Cleveland at the Taussig Cancer Center on September 16, 2017.
Cancer Type:
Transcript I think there are several goals when treating a patient with advanced non-small cell lung cancer. For one I think we want to extend life,...
Cancer Journey:
Cancer Type:

Articles

Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Cancer Journey:
Cancer Type:
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.
Cancer Journey:
Cancer Type:
Dr. West moderates a question & answer session with Drs. Karen Reckamp and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.
Cancer Journey:
Cancer Type:
Every few months I see a patient who reminds me of the fallability of mutation testing. One of the brightest rays of hope in the management of lung...
Cancer Journey:
Cancer Type:
Almost exactly a year ago, I reported that the large MARQUEE trial of EGFR inhibitor Tarceva (erlotinib) plus either the MET inhibitor tivantinib (...
Cancer Journey:
Cancer Type:

Community Forum

No Result Found